The DOI matches its Crossref record.
In Vitro Activities of New and Conventional Antifungal Agents against Clinical Scedosporium Isolates
Open accessAbstract
The susceptibilities of 13 clinical isolates of Scedosporium apiospermum and 55 clinical isolates of S. prolificans to new and conventional drugs belonging to three different classes of antifungal agents, the azoles (miconazole, itraconazole, voriconazole, UR-9825, posaconazole), the polyenes (amphotericin B, nystatin and liposomal nystatin), and allylamines (terbinafine), were studied by use of proposed standard M38-P of NCCLS. Low growth-inhibitory antifungal activities were found in vitro for most of the drugs tested against S. prolificans isolates, with the MICs at which 90% of isolates are inhibited (MIC 90 s) being >8 μg/ml; the MIC 90 s of voriconazole and UR-9825, however, were 4 μg/ml.S. apiospermum isolates were more susceptible in vitro, with the highest activity exhibited by voriconazole (MIC 90 s, 0.5 μg/ml), followed by miconazole (MIC 90 s, 1 μg/ml), UR-9825 and posaconazole (MIC 90 s, 2 μg/ml), and itraconazole (MIC 90 s, 4 μg/ml). The MICs of terbinafine, amphotericin B, and the two formulations of nystatin (for which no statistically significant differences in antifungal activities were found for the two species) for S. apiospermum isolates were high. Cross-resistance was observed among all the azoles except posaconazole and among all the polyenes except the lipid formulation. A distribution analysis was performed with the MICs of each drug and for each species. Bimodal and skewed MIC distributions were obtained, and cutoffs indicating the borders of different MIC subpopulations of the distributions were determined on the basis of the normal plot technique. These cutoffs were in many cases reproducible between 48 and 72 h.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Infections Caused by Scedosporium spp
Cortez, K. J., Roilides, E., Quiroz-Telles, F., Meletiadis, J., Antachopoulos, C., Knudsen, T., Buchanan, W., Milanovich, J., Sutton, D. A., Fothergill, A., et al. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00039-07 · Cited by 786
Self-citationPfaller, M. A., & Diekema, D. J. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.10.4419-4431.2004 · Cited by 694
Resistance to Antifungal Agents: Mechanisms and Clinical Impact
Kanafani, Z. A., & Perfect, J. R. (2008) · Clinical Infectious Diseases · doi:10.1086/524071 · Cited by 619
Melanized Fungi in Human Disease
Revankar, S. G., & Sutton, D. A. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00019-10 · Cited by 569
Tortorano, A. M., Richardson, M., Roilides, E., van Diepeningen, A., Caira, M., Munoz, P., Johnson, E., Meletiadis, J., Pana, Z.-D., Lackner, M., et al. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12465 · Cited by 523
Self-citationSabatelli, F., Patel, R., Mann, P. A., Mendrick, C. A., Norris, C. C., Hare, R., Loebenberg, D., Black, T. A., & McNicholas, P. M. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00163-06 · Cited by 491
Hoenigl, M., Salmanton-García, J., Walsh, T. J., Nucci, M., Neoh, C. F., Jenks, J. D., Lackner, M., Sprute, R., Al-Hatmi, A. M. S., Bassetti, M., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30784-2 · Cited by 470
Self-citationPharmacokinetic/Pharmacodynamic Profile of Posaconazole
Li, Y., Theuretzbacher, U., Clancy, C. J., Nguyen, M. H., & Derendorf, H. (2010) · Clinical Pharmacokinetics · doi:10.2165/11319340-000000000-00000 · Cited by 450
Invasive Fungal Pathogens: Current Epidemiological Trends
Pfaller, M. A., Pappas, P. G., & Wingard, J. R. (2006) · Clinical Infectious Diseases · doi:10.1086/504490 · Cited by 448
Breakthrough Fungal Infections in Stem Cell Transplant Recipients Receiving Voriconazole
Imhof, A., Balajee, S. A., Fredricks, D. N., Englund, J. A., & Marr, K. A. (2004) · Clinical Infectious Diseases · doi:10.1086/423274 · Cited by 402
Husain, S., Munoz, P., Forrest, G., Alexander, B. D., Somani, J., Brennan, K., Wagener, M. M., & Singh, N. (2005) · Clinical Infectious Diseases · doi:10.1086/426445 · Cited by 401
The changing face of epidemiology of invasive fungal disease in Europe
Lass‐Flörl, C. (2009) · Mycoses · doi:10.1111/j.1439-0507.2009.01691.x · Cited by 369
Nett, J. E., & Andes, D. R. (2016) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2015.10.012 · Cited by 351
Courtney, R., Wexler, D., Radwanski, E., Lim, J., & Laughlin, M. (2004) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01977.x · Cited by 327
Combination Treatment of Invasive Fungal Infections
Mukherjee, P. K., Sheehan, D. J., Hitchcock, C. A., & Ghannoum, M. A. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.1.163-194.2005 · Cited by 308
Newer Systemic Antifungal Agents: Pharmacokinetics, Safety and Efficacy
Boucher, H. W., Groll, A. H., Chiou, C. C., & Walsh, T. J. (2004) · Drugs · doi:10.2165/00003495-200464180-00001 · Cited by 305
Courtney, R., Pai, S., Laughlin, M., Lim, J., & Batra, V. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.9.2788-2795.2003 · Cited by 299
Cuenca-Estrella, M., Gomez-Lopez, A., Mellado, E., Buitrago, M. J., Monzon, A., & Rodriguez-Tudela, J. L. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.3.917-921.2006 · Cited by 298
Scedosporium apiospermum: changing clinical spectrum of a therapy-refractory opportunist*
Guarro, J., Kantarcioglu, A. S., Horré, R., Luis Rodriguez-Tudela, J., Cuenca Estrella, M., Berenguer, J., & Sybren De Hoog, G. (2006) · Medical Mycology · doi:10.1080/13693780600752507 · Cited by 297
Treatment of Scedosporiosis with Voriconazole: Clinical Experience with 107 Patients
Troke, P., Aguirrebengoa, K., Arteaga, C., Ellis, D., Heath, C. H., Lutsar, I., Rovira, M., Nguyen, Q., Slavin, M., & Chen, S. C. A. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01388-07 · Cited by 294
Species-Specific Antifungal Susceptibility Patterns of Scedosporium and Pseudallescheria Species
Lackner, M., de Hoog, G. S., Verweij, P. E., Najafzadeh, M. J., Curfs-Breuker, I., Klaassen, C. H., & Meis, J. F. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05910-11 · Cited by 290
Self-citationEpidemiology and outcome of Scedosporium prolificans infection, a review of 162 cases
Rodriguez-Tudela, J. L., Rodriguez-Tudela, J. L., Berenguer, J., Guarro, J., Kantarcioglu, A. S., Horre, R., Sybren De Hoog, G., & Cuenca-Estrella, M. (2009) · Medical Mycology · doi:10.1080/13693780802524506 · Cited by 269
Marangon, F. B., Miller, D., Giaconi, J. A., & Alfonso, E. C. (2004) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2003.11.078 · Cited by 264
Meletiadis, J., Mouton, J. W., Meis, J. F. G. M., & Verweij, P. E. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.1.106-117.2003 · Cited by 253
Self-citationEspinel-Ingroff, A., Chaturvedi, V., Fothergill, A., & Rinaldi, M. G. (2002) · Journal of Clinical Microbiology · doi:10.1128/jcm.40.10.3776-3781.2002 · Cited by 167
Hata, K., Horii, T., Miyazaki, M., Watanabe, N.-A., Okubo, M., Sonoda, J., Nakamoto, K., Tanaka, K., Shirotori, S., Murai, N., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00366-11 · Cited by 149
New generation azole antifungals in clinical investigation
Girmenia, C. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903176407 · Cited by 107
Metadata
- Authors
- Meletiadis, J., Meis, J. F. G. M., Mouton, J. W., Rodriquez-Tudela, J. L., Donnelly, J. P., Verweij, P. E., & the EUROFUNG Network
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2002-01
- Volume
- 46
- Issue
- 1
- Pages
- 62-68
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2128483390
- Cited by
- 233
- References
- 0
- FWCI
- 15.68
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.